Dimerix Limited

Equities

DXB

AU000000DXB7

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 02:10:52 2024-04-24 am EDT			5-day change	1st Jan Change
0.335 ^AUD	+9.84%		+17.54%	+63.41%

Apr. 22	Dimerix Posts AU$35.2 Million Cash, AU$3.3 Million Operating Cash Outflows for March Quarter	MT
Apr. 19	Euroz Hartleys Starts Dimerix at Speculative Buy With AU$0.80 Price Target	MT

Dimerix Limited Announces Global REMAP-CAP Platform Trial Protocol To Include DMX-200

June 03, 2020 at 06:38 pm EDT

Dimerix Limited announced that DMX-200 has been selected for inclusion in the protocol as a new treatment arm in the global Randomised, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) program aimed at treating patients with Acute Respiratory Distress Syndrome (ARDS) as a result of COVID-19. The REMAP-CAP program is endorsed by the World Health Organisation (WHO), and designated as a Pandemic Special Study.

Latest news about Dimerix Limited

Dimerix Posts AU$35.2 Million Cash, AU$3.3 Million Operating Cash Outflows for March Quarter	Apr. 22	MT
Euroz Hartleys Starts Dimerix at Speculative Buy With AU$0.80 Price Target	Apr. 19	MT
Dimerix Raises AU$20 Million for Kidney Disease Study	Mar. 12	MT
Dimerix Expanding Kidney Drug Study After DMX-200 Performs Better than Placebo	Mar. 10	MT
Dimerix Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 25	CI
Dimerix Limited Announces Appointment of Mark Diamond as Director	Nov. 30	CI
Dimerix Secures Investigational New Drug Approval for Kidney Disease Medication in China; Shares Rally 11%	Nov. 27	MT
Dimerix Appoints Nonexecutive Chair	Nov. 19	MT
Dimerix Receives AU$10.7 Million Upfront Payment for Commercialization Rights	Nov. 07	MT
Dimerix Appoints Medical Chief	23-10-22	MT
Dimerix Limited Announces Appointment of Dr David Fuller as Chief Medical Officer	23-10-22	CI
Softer US Employment Data End Australian Shares' Three-Day Losing Streak	23-10-05	MT
Dimerix Surges 154% After Securing License Deal for Kidney Disease Drug	23-10-05	MT
Dimerix Secures Conditional US FDA Clearance for Kidney Medication Brand Name	23-09-25	MT
Dimerix Secures Regulatory Nod to Conduct Kidney Disease Drug Trial in Malaysia	23-09-22	MT
Dimerix Secures AU$9 Million R&D Tax Rebate; Shares Rise 3%	23-09-12	MT
Dimerix Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-29	CI
Dimerix Secures Approval for Pediatric Kidney Disease Plan in Europe	23-07-05	MT
Dimerix Secures Study Design Approval in China for Phase Three Kidney Disease Trial; Shares Rise 6%	23-07-02	MT
Dimerix Raising AU$12 Million to Continue Clinical Program; Shares Down 7%	23-05-03	MT
Dimerix Limited Appoints Clinton Snow New Non-Executive Director to the Board, Effective 01 May 2023	23-04-30	CI
Dimerix Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-26	CI
Dimerix Secures AU$2.8 Million in Prepayment of R&D Tax Rebate; Shares Rise 8%	23-02-16	MT
Dimerix Secures Safety Approval for Phase 3 Kidney Drug Trial	23-02-09	MT
Dimerix Limited Announces Successful Completion of DSMB Review of Phase 3 FSGS Trial	23-02-08	CI

Chart Dimerix Limited

Duration

Period

More charts

Company Profile

Dimerix Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is focused on developing new therapies in areas with unmet medical needs for global markets. It is focused on developing its products, DMX-200, for Focal Segmental Glomerulosclerosis (FSGS), respiratory complications associated with COVID-19 and Diabetic Kidney Disease and is developing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD). Its DMX-200 and DMX-700 are identified using its assay, Receptor Heteromer Investigation Technology (Receptor-HIT), which is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities. Its products target multiple global territories, with the initial focus predominantly on the United States and European markets. It has completed two Phase 2 studies: one in FSGS and one in diabetic kidney disease. Receptor-HIT is licensed to Excellerate Bioscience.

Sector

Biotechnology & Medical Research

Calendar

2024-08-26 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
DIMERIX LIMITED	+63.41%	119M
IQVIA HOLDINGS INC.	+4.09%	43.84B
LONZA GROUP AG	+46.68%	41.25B
MODERNA, INC.	+9.45%	41.68B
CELLTRION, INC.	-10.92%	27.04B
ICON PUBLIC LIMITED COMPANY	+9.32%	25.53B
ALNYLAM PHARMACEUTICALS, INC.	-24.87%	18.18B
MEDPACE HOLDINGS, INC.	+29.70%	12.29B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.28%	12.29B
UNITED THERAPEUTICS CORPORATION	+7.78%	11.15B

Other Biotechnology & Medical Research